Experienced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Nader Sanai

Neurosurgery
2910 N 3rd Ave, Suite 200, 
Phoenix, AZ 
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
2910 N 3rd Ave, Suite 200, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nader Sanai is a Neurosurgery provider in Phoenix, Arizona. Dr. Sanai is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Brain Tumor, Glioma, Glioblastoma, Awake Craniotomy, and Gastrostomy.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Diffuse Midline Glioma H3 K27M-Mutant.

Specialties
Neurosurgery
Licenses
Neurological Surgery in AZ
Hospital Affiliations
Yuma Regional Medical Center
St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

NEUROSURGICAL ASSOCIATES LTD
2910 N 3rd Ave, Suite 200, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Completed
Publish Date: May 30, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Everolimus
Study Phase: Early Phase 1
A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Active_not_recruiting
Publish Date: March 14, 2025
Intervention Type: Drug
Study Drug: Ribociclib
Study Phase: Early Phase 1
A Phase 0/2 Study of LY3214996 (ERK Inhibitor) in Combination With Abemaciclib (CDK4 and 6 Inhibitor) in Recurrent Glioblastoma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/2 Study of LY3214996 (ERK Inhibitor) in Combination With Abemaciclib (CDK4 and 6 Inhibitor) in Recurrent Glioblastoma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, LY3214996
Study Phase: Early Phase 1
A Phase 0/2 Clinical Trial of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma Patients
A Phase 0/2 Clinical Trial of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pamiparib, Olaparib, Temozolomide
Study Phase: Early Phase 1
A Phase 0 'Trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma
A Phase 0 'Trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2025
Intervention Type: Radiation, Drug
Study Drug: Niraparib
Study Phase: Early Phase 1
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Enrollment Status: Suspended
Publish Date: September 19, 2024
Intervention Type: Combination product
Study Drug: SONALA-001+MR-Guided Focused Ultrasound device
Study Phase: Phase 2
A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort
A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort
Enrollment Status: Terminated
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Early Phase 1
Barrow 5-ALA Intraoperative Confocal Evaluation Trial
Barrow 5-ALA Intraoperative Confocal Evaluation Trial
Enrollment Status: Completed
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: 5-Aminolevulinic acid
Study Phase: Phase 3
A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Completed
Publish Date: December 11, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 10 Less Clinical Trials

129 Total Publications

Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization.
Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization.
Journal: Pharmaceutics
Published: March 19, 2025
Similar Doctors
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Jason Hauptman
Neurosurgery
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Jason Hauptman
Neurosurgery
1919 E Thomas Rd, 
Phoenix, AZ 
 (2.2 miles away)
602-933-0920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Hauptman is a Neurosurgery provider in Phoenix, Arizona. Dr. Hauptman is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Hydrocephalus, Hemimegalencephaly, Epilepsy, Posterior Fossa Decompression, and Deep Brain Stimulation.

Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Kris A. Smith
Neurosurgery
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Kris A. Smith
Neurosurgery

Neurosurgical Associates Ltd

2910 N 3rd Ave, Suite 200, 
Phoenix, AZ 
 (0.1 miles away)
602-406-3181
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kris Smith is a Neurosurgery provider in Phoenix, Arizona. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Brain Tumor, Glioma, Astrocytoma, Awake Craniotomy, and Deep Brain Stimulation.

Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Michael T. Lawton
Neurosurgery
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Michael T. Lawton
Neurosurgery

Neurosurgical Associates Ltd

2910 N 3rd Ave, Suite 200, 
Phoenix, AZ 
 (0.1 miles away)
602-406-3181
Languages Spoken:
English
See accepted insurances

Michael Lawton is a Neurosurgery provider in Phoenix, Arizona. Dr. Lawton is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Arteriovenous Malformation, Cerebral Arteriovenous Malformation, Brain Aneurysm, Cerebral Artery Bypass Surgery, and Extracranial-Intracranial Bypass Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sanai's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 16 Distinguished Conditions
View All 7 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile